Investment Thesis
Genprex is a pre-revenue pharmaceutical company burning $3.1M quarterly with only $18M in cash, providing approximately 18 months of operational runway. While the balance sheet is clean with minimal debt and excellent liquidity, the lack of revenue combined with ongoing operational losses reflects a high-risk biotech venture entirely dependent on uncertain clinical trial outcomes and regulatory success.
Strengths
- Strong cash position of $18.0M providing adequate near-term liquidity
- Minimal debt with Debt/Equity ratio of 0.00x and clean balance sheet structure
- Excellent current ratio of 5.61x demonstrating strong ability to meet short-term obligations
Risks
- Pre-revenue company with zero revenue and $4.5M quarterly operating losses
- Quarterly cash burn of $3.1M limits operational runway to approximately 18 months without additional capital
- High-risk biotech model with uncertain clinical trial results and lengthy regulatory approval timelines
Key Metrics to Watch
- Quarterly cash burn trend and remaining months of runway
- Clinical trial milestones and regulatory submission progress
- Capital raise activities and equity dilution impact on shareholders
Financial Metrics
Revenue
0.0
Net Income
-4.5M
EPS (Diluted)
$0.00
Free Cash Flow
-3.1M
Total Assets
20.3M
Cash
18.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-26.4%
ROA
-22.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
5.61x
Quick Ratio
5.61x
Debt/Equity
0.00x
Debt/Assets
16.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:35:09.318330 |
Data as of: 2026-03-31 |
Powered by Claude AI